Ablative Therapy for Metastatic Liver Cancer-Role of SPIO-enhanced MRI
|
Accession number;04A0328377
|
| Title;Ablative Therapy for Metastatic Liver Cancer-Role of SPIO-enhanced MRI |
| Author;
WAKABAYASHI GO
(Sch. of Med., Keio Univ.)
TANABE MINORU
(Sch. of Med., Keio Univ.)
UEDA MASAKAZU
(Sch. of Med., Keio Univ.)
SHIMAZU MOTOHIDE
(Sch. of Med., Keio Univ.)
KAWACHI SHIGEYUKI
(Sch. of Med., Keio Univ.)
KITAJIMA MASAKI
(Sch. of Med., Keio Univ.)
|
Journal Title;Japanisch-Deutsche Medizinische Berichte
|
Journal Code:S0730B
|
ISSN:0912-0351
|
|
VOL.49;NO.1;PAGE.58-66(2004)
|
| Figure&Table&Reference;FIG.11, TBL.3, REF.3 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;Although ablative therapy for hepatocellular carcinoma is widely accepted as a choice of treatment modality, the role of ablation for metastatic liver cancer remains to be defined. Resection is a first-choice treatment for resectable colorectal liver metastases, because it achieves cure rates of 20-30% for the disease. The generally accepted indication of ablative therapy for metastatic liver cancer is only for unresectable metastases. However, the definition of unresectable metastases differs among institutes. We propose the role of ablation for metastatic liver cancer as a bridge between chemotherapy and resection. Argon-based cryoablation is newly developed technology with which large tumors and/or multiple tumors can be ablated using multiple probe freezing, being an optimal ablative device for metastatic liver cancer. Our preliminary results from 100 cases of cryoablation for liver cancer show acceptable rates of local recurrence and postoperative morbidity. (author abst.) |
|
|
|
Related Articles;
|
|
